Civeta

Civetta Therapeutics develops novel small molecule therapies by precisely targeting beta-propeller domains to combat cancer and other significant diseases. The company focuses on identifying and modulating these specific protein structures, essential for various cellular functions. This approach aims to create differentiated treatments capable of disrupting critical disease pathways.

Founded in 2019 by William R. Sellers and Eric Fischer, Civetta Therapeutics originated from their profound insight into the therapeutic potential of beta-propeller proteins. Sellers, a prominent oncology researcher, combined with Fischer’s expertise, recognized that modulating these structures could yield effective and distinct drug candidates for challenging medical conditions.

The company envisions its specialized therapies benefiting patients facing a range of serious illnesses, particularly those afflicted with cancer. Civetta Therapeutics strives to translate advanced scientific understanding of beta-propeller biology into transformative medicines, expanding treatment options and improving patient outcomes where medical need is high.